The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

Garden, Benjamin C.; Wu, Shenhong; Lacouture, Mario E.

doi:10.1016/j.jaad.2011.10.009

Cited by 69 publications

(40 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta‐analysis of patients receiving erlotinib ( n = 2,717) and gefitinib ( n = 3,002) found an overall incidence of pruritus of 21% for each agent and the incidence for high‐grade pruritus to be 2.3% and 1%, respectively . A meta‐analysis of risk and incidence of nail toxicities associated with erlotinib and other EGFR inhibitors found that, among patients ( n = 488) receiving erlotinib for the treatment of NSCLC, endometrial cancer, or hepatocellular carcinoma, 16.3% (95% confidence interval [CI], 12.4–21.1) had nail toxicity of any grade, and 1.8% (95% CI, 0.8–3.8) had high‐grade nail toxicity .…”

Section: Dermatologic Toxicities Among First‐ and Second‐generation Ementioning

confidence: 99%

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Appropriate prevention and management of dermatologic adverse events (dAEs) associated with the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) may help patients to continue therapy and lessen any negative impact on their quality of life. EGFR-TKIs are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; however, dAEs associated with third-generation EGFR-TKIs are lower in frequency and severity. Before therapy, health care providers should discuss the potential osimertinib-associated dAEs and encourage patients to report their dAEs. Patients should also be educated on prophylactic measures to minimize the severity of dAEs and the importance of adherence to the treatment regimen.

show abstract

Section: Dermatologic Toxicities Among First‐ and Second‐generation Ementioning

confidence: 99%

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, previous meta-analyses have shown an increased risk of rash, nail changes, hypokalemia, hypomagnesemia and venous thromboembolism [7][8][9][10][11]. Additionally, infectious complications associated with anti-EGFR mAbs have been reported in randomized controlled trials (RCTs).…”

Section: Introductionmentioning

confidence: 99%

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis

Funakoshi¹,

Suzuki

Tamura

2014

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…Nail changes occur with 34.9% and 17.2% of patients receiving taxanes and EGFR inhibitors, respectively 20,21. It has been reported that taxanes are associated most commonly with erythema, edema, exudate, suppuration, and onycholysis.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases

Capriotti¹,

Capriotti²,

Pelletier³

et al. 2017

CMAR

View full text Add to dashboard Cite

BackgroundNail changes are known to occur during the use of chemotherapy for a variety of malignancies, particularly those treated with taxanes and EGFR inhibitors. There are currently no actively recruiting prospective clinical trials investigating potential treatments. There are also no US Food and Drug Administration-approved medical treatments for chemotherapy-associated paronychia and no consensus on the best way to treat these common chemotherapy-induced events.MethodsA retrospective review of all cases presenting to a single dermatology private practice from June 2016 to January 2017 identified nine patients with chemotherapy-associated paronychia seeking treatment. Each patient was prescribed a topical solution comprised of 2% povidone–iodine in a dimethylsulfoxide vehicle that was prepared by a licensed compounding pharmacy. Patients were seen at 3 week and 6 week follow-up visits.ResultsAll 9/9 patients demonstrated complete or partial resolution. The number of nails involved for each patient ranged from 4–12. There were a total of 58 nails affected in the case series, and 44/58 (76%) resolved overall. The treatment was well tolerated.ConclusionThe topical povidone–iodine/dimethylsufoxide solution described is very effective in alleviating the signs and symptoms of paronychia associated with chemotherapy. This novel combination warrants further investigation in randomized, controlled trials to further elucidate its clinical utility.

show abstract

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

Cited by 69 publications

References 45 publications

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases

Contact Info

Product

Resources

About

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

Cited by 69 publications

References 45 publications

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis

Chemotherapy-associated paronychia treated with 2% povidone&ndash;iodine: a series of cases

Contact Info

Product

Resources

About

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases